Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions
Open Access
- 1 November 2017
- journal article
- review article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 4, 131-138
Abstract
The only US Food and Drug Administration (FDA)-approved first-line systemic therapy for hepatocellular carcinoma (HCC) is sorafenib; however, resistance or intolerance to sorafenib is unfortunately common. In this review, we briefly describe systemic therapies that can be considered for patients with HCC who show resistance or intolerance to sorafenib. For all patients with HCC who need systemic therapy, we strongly advocate for participation in clinical trials. Cytotoxic chemotherapy plays a minor role in the treatment of advanced HCC, with some data supporting the use of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) and GEMOX (gemcitabine-oxaliplatin). Multi-target kinase inhibitors such as lenvantinib and regorafenib have recently met their primary endpoints as first- and second-line therapy, respectively, with regorafenib now representing the only FDA-approved drug for second-line treatment of HCC. Other targeted therapies remain under investigation, but results so far have not significantly changed clinical practice. Immunotherapy is an interesting area of research in the treatment of HCC with preclinical and early clinical data demonstrating exciting results; thus numerous investigational studies are currently focusing on immunotherapy in the treatment of HCC. While systemic treatment options in HCC remain a challenge for providers, in this review, we summarize the current literature and highlight areas of progress with respect to the treatment of patients with HCC and resistance or intolerance to sorafenib.Keywords
This publication has 56 references indexed in Scilit:
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- New knowledge of the mechanisms of sorafenib resistance in liver cancerActa Pharmacologica Sinica, 2017
- Population attributable fractions of risk factors for hepatocellular carcinoma in the United StatesCancer, 2016
- Advancing clinical oncology through genome biology and technologyGenome Biology, 2014
- Molecular Therapies in Hepatocellular Carcinoma: What Can We Target?Digestive Diseases and Sciences, 2014
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From AsiaJournal of Clinical Oncology, 2013
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2005
- Hepatocellular carcinomaThe Lancet, 2003
- Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedulesCancer, 2003